<p>Assenagon Asset Management S.A. 在最近向证券交易委员会提交的文件中表示，在第三季度减少了对阿斯利康制药（NASDAQ:AZN - 免费报告）股票的持仓，降幅为 48.7%。该公司在此期间出售了 569,162 股后，持有 598,354 股阿斯利康的股票。根据其最近向证券交易委员会提交的文件，Assenagon Asset Management S.A. 在阿斯利康的持股价值为 45,906,000 美元。</p>
<ul>
<li>D-Wave 与量子竞争对手相比如何？</li>
</ul>
<p>其他几家机构投资者和对冲基金也买卖了该公司的股票。Primecap Management Co. CA 在第二季度将其在阿斯利康的持仓增加了 1.3%。Primecap Management Co. CA 目前持有 41,200,091 股阿斯利康的股票，价值 2,879,062,000 美元，此前在上个季度购买了 538,606 股。Franklin Resources Inc. 在第二季度将其在阿斯利康的持仓增加了 0.9%。Franklin Resources Inc. 目前持有 21,298,394 股阿斯利康的股票，价值 1,488,332,000 美元，此前在上个季度购买了 196,401 股。Fisher Asset Management LLC 在第二季度将其在阿斯利康的持仓增加了 2.6%。Fisher Asset Management LLC 目前持有 20,695,979 股阿斯利康的股票，价值 1,446,235,000 美元，此前在此期间购买了 530,520 股。Jennison Associates LLC 在第二季度将其在阿斯利康的持仓增加了 15.2%。Jennison Associates LLC 目前持有 12,167,365 股阿斯利康的股票，价值 850,255,000 美元，此前在上个季度购买了 1,605,133 股。最后，Ameriprise Financial Inc. 在第二季度将其在阿斯利康的持仓增加了 2.1%。Ameriprise Financial Inc. 目前持有 5,046,992 股阿斯利康的股票，价值 351,734,000 美元，此前在上个季度购买了 104,625 股。目前，20.35% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>最近，一些分析师对 AZN 股票发布了报告。摩根士丹利在 12 月 3 日的研究报告中重申了 “增持” 评级，并设定了 103.00 美元的目标价。杰富瑞金融集团在 10 月 27 日的研究报告中开始覆盖阿斯利康的股票，并给予 “买入” 评级。德意志银行在 10 月 16 日的研究报告中将阿斯利康的股票评级从 “持有” 下调至 “卖出”。古根海姆在 12 月 3 日的报告中重申了对阿斯利康的 “买入” 评级。最后，汇丰银行在 12 月 10 日的研究报告中重申了 “买入” 评级，并设定了 108.00 美元的目标价。八位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 95.75 美元。</p>
<ul>
<li>Tempus AI 股票：是时候加倍下注还是撤退？</li>
</ul>
<p><strong>获取我们关于阿斯利康的最新报告</strong></p>
<h2>阿斯利康股票下跌 1.6%</h2>
<p>阿斯利康股票在周四开盘价为 89.86 美元。该公司的市值为 2786.9 亿美元，市盈率为 29.85，市盈增长比率为 1.69，贝塔值为 0.32。阿斯利康制药的股价一年低点为 61.24 美元，一年高点为 94.01 美元。该公司的 50 日移动平均价格为 87.35 美元，200 日移动平均价格为 79.57 美元。该公司的债务与股本比率为 0.54，速动比率为 0.69，流动比率为 0.88。</p>
<ul>
<li>Cellectis 制定 2025 年计划，受益于阿斯利康交易</li>
</ul>
<p>阿斯利康（NASDAQ:AZN - 获取免费报告）在 11 月 6 日最后一次公布季度财报。该公司报告每股收益（EPS）为 1.19 美元，超出分析师共识预期的 1.14 美元，超出 0.05 美元。阿斯利康的净利润率为 16.17%，股本回报率为 32.89%。该公司在本季度的收入为 151.9 亿美元，而分析师预期为 147.5 亿美元。在去年同期，该公司每股收益为 2.08 美元。该公司的收入同比增长 12.0%。分析师预测阿斯利康制药在当前财年将发布每股收益 4.51 美元。</p>
<h2>阿斯利康简介</h2>
<p>（免费报告）</p>
<p>阿斯利康制药是一家生物制药公司，专注于处方药的发现、开发、生产和商业化。该公司的市场产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，涵盖心血管、肾脏、代谢和肿瘤领域。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比阿斯利康更具吸引力</li>
<li>股票评级和建议：理解分析师评级</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>如何从成长投资中获利</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
<p><strong>想看看其他对冲基金持有的 AZN 股票吗？</strong> 访问 HoldingsChannel.com，获取阿斯利康制药（NASDAQ:AZN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在阿斯利康吗？</h2>
<p>在考虑阿斯利康之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿斯利康并不在名单上。</p>
<p>虽然阿斯利康目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿斯利康

阿斯利康制药

<p>Assenagon Asset Management S.A. 在第三季度将其在阿斯利康制药的持股减少了 48.7%，出售了 569,162 股。该公司的持股现价值为 4590 万美元。其他机构投资者也调整了在阿斯利康的持仓。该公司报告了强劲的季度收益，收入同比增长 12%。分析师维持 “适度买入” 的共识，目标价为 95.75 美元。阿斯利康的股票开盘价为 89.86 美元，市值为 2786.9 亿美元</p>

<p>Assenagon Asset Management S.A. lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 48.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 598,354 shares of the company's stock after selling 569,162 shares during the period. Assenagon Asset Management S.A.'s holdings in AstraZeneca were worth $45,906,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向证券交易委员会提交的文件中表示，在第三季度减少了对阿斯利康制药（NASDAQ:AZN - 免费报告）股票的持仓，降幅为 48.7%。该公司在此期间出售了 569,162 股后，持有 598,354 股阿斯利康的股票。根据其最近向证券交易委员会提交的文件，Assenagon Asset Management S.A. 在阿斯利康的持股价值为 45,906,000 美元。</p>
</div><ul>
<li>How Does D-Wave Stack Up Against Quantum Competitors?</li>
</ul>
<div class="lb-trans"><ul>
<li>D-Wave 与量子竞争对手相比如何？</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also bought and sold shares of the company. Primecap Management Co. CA grew its position in shares of AstraZeneca by 1.3% during the 2nd quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company's stock valued at $2,879,062,000 after purchasing an additional 538,606 shares in the last quarter. Franklin Resources Inc. raised its position in shares of AstraZeneca by 0.9% in the second quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company's stock worth $1,488,332,000 after buying an additional 196,401 shares in the last quarter. Fisher Asset Management LLC boosted its stake in AstraZeneca by 2.6% during the second quarter. Fisher Asset Management LLC now owns 20,695,979 shares of the company's stock valued at $1,446,235,000 after buying an additional 530,520 shares during the period. Jennison Associates LLC grew its position in AstraZeneca by 15.2% during the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company's stock worth $850,255,000 after buying an additional 1,605,133 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in AstraZeneca by 2.1% during the second quarter. Ameriprise Financial Inc. now owns 5,046,992 shares of the company's stock worth $351,734,000 after buying an additional 104,625 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金也买卖了该公司的股票。Primecap Management Co. CA 在第二季度将其在阿斯利康的持仓增加了 1.3%。Primecap Management Co. CA 目前持有 41,200,091 股阿斯利康的股票，价值 2,879,062,000 美元，此前在上个季度购买了 538,606 股。Franklin Resources Inc. 在第二季度将其在阿斯利康的持仓增加了 0.9%。Franklin Resources Inc. 目前持有 21,298,394 股阿斯利康的股票，价值 1,488,332,000 美元，此前在上个季度购买了 196,401 股。Fisher Asset Management LLC 在第二季度将其在阿斯利康的持仓增加了 2.6%。Fisher Asset Management LLC 目前持有 20,695,979 股阿斯利康的股票，价值 1,446,235,000 美元，此前在此期间购买了 530,520 股。Jennison Associates LLC 在第二季度将其在阿斯利康的持仓增加了 15.2%。Jennison Associates LLC 目前持有 12,167,365 股阿斯利康的股票，价值 850,255,000 美元，此前在上个季度购买了 1,605,133 股。最后，Ameriprise Financial Inc. 在第二季度将其在阿斯利康的持仓增加了 2.1%。Ameriprise Financial Inc. 目前持有 5,046,992 股阿斯利康的股票，价值 351,734,000 美元，此前在上个季度购买了 104,625 股。目前，20.35% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of analysts have recently issued reports on AZN shares. Morgan Stanley reiterated an &#34;overweight&#34; rating and set a $103.00 price target on shares of AstraZeneca in a research report on Wednesday, December 3rd. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research note on Monday, October 27th. They issued a &#34;buy&#34; rating on the stock. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Thursday, October 16th. Guggenheim reissued a &#34;buy&#34; rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, HSBC restated a &#34;buy&#34; rating and set a $108.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 10th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $95.75.</p>
<div class="lb-trans"><p>最近，一些分析师对 AZN 股票发布了报告。摩根士丹利在 12 月 3 日的研究报告中重申了 “增持” 评级，并设定了 103.00 美元的目标价。杰富瑞金融集团在 10 月 27 日的研究报告中开始覆盖阿斯利康的股票，并给予 “买入” 评级。德意志银行在 10 月 16 日的研究报告中将阿斯利康的股票评级从 “持有” 下调至 “卖出”。古根海姆在 12 月 3 日的报告中重申了对阿斯利康的 “买入” 评级。最后，汇丰银行在 12 月 10 日的研究报告中重申了 “买入” 评级，并设定了 108.00 美元的目标价。八位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 95.75 美元。</p>
</div><ul>
<li>Tempus AI Stock: Time to Double Down or Cut and Run?</li>
</ul>
<div class="lb-trans"><ul>
<li>Tempus AI 股票：是时候加倍下注还是撤退？</li>
</ul>
</div><p><strong>Get Our Latest Report on AstraZeneca</strong></p>
<div class="lb-trans"><p><strong>获取我们关于阿斯利康的最新报告</strong></p>
</div><h2>AstraZeneca Trading Down 1.6%</h2>
<div class="lb-trans"><h2>阿斯利康股票下跌 1.6%</h2>
</div><p>AZN stock opened at $89.86 on Thursday. The company has a market capitalization of $278.69 billion, a PE ratio of 29.85, a price-to-earnings-growth ratio of 1.69 and a beta of 0.32. AstraZeneca PLC has a one year low of $61.24 and a one year high of $94.01. The company's 50 day moving average price is $87.35 and its two-hundred day moving average price is $79.57. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88.</p>
<div class="lb-trans"><p>阿斯利康股票在周四开盘价为 89.86 美元。该公司的市值为 2786.9 亿美元，市盈率为 29.85，市盈增长比率为 1.69，贝塔值为 0.32。阿斯利康制药的股价一年低点为 61.24 美元，一年高点为 94.01 美元。该公司的 50 日移动平均价格为 87.35 美元，200 日移动平均价格为 79.57 美元。该公司的债务与股本比率为 0.54，速动比率为 0.69，流动比率为 0.88。</p>
</div><ul>
<li>Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal</li>
</ul>
<div class="lb-trans"><ul>
<li>Cellectis 制定 2025 年计划，受益于阿斯利康交易</li>
</ul>
</div><p>AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The company had revenue of $15.19 billion during the quarter, compared to analysts' expectations of $14.75 billion. During the same quarter in the prior year, the company earned $2.08 EPS. The firm's revenue was up 12.0% on a year-over-year basis. As a group, analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>阿斯利康（NASDAQ:AZN - 获取免费报告）在 11 月 6 日最后一次公布季度财报。该公司报告每股收益（EPS）为 1.19 美元，超出分析师共识预期的 1.14 美元，超出 0.05 美元。阿斯利康的净利润率为 16.17%，股本回报率为 32.89%。该公司在本季度的收入为 151.9 亿美元，而分析师预期为 147.5 亿美元。在去年同期，该公司每股收益为 2.08 美元。该公司的收入同比增长 12.0%。分析师预测阿斯利康制药在当前财年将发布每股收益 4.51 美元。</p>
</div><h2>AstraZeneca Profile</h2>
<div class="lb-trans"><h2>阿斯利康简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p>
<div class="lb-trans"><p>阿斯利康制药是一家生物制药公司，专注于处方药的发现、开发、生产和商业化。该公司的市场产品包括 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Lokelma、Roxadustat、Andexxa、Crestor、Seloken、Onglyza、Bydureon、Fasenra、Breztri、Symbicort、Saphnelo、Tezspire、Pulmicort、Bevespi 和 Daliresp，涵盖心血管、肾脏、代谢和肿瘤领域。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AstraZeneca</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>How to Profit From Growth Investing</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比阿斯利康更具吸引力</li>
<li>股票评级和建议：理解分析师评级</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>如何从成长投资中获利</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AZN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 AZN 股票吗？</strong> 访问 HoldingsChannel.com，获取阿斯利康制药（NASDAQ:AZN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AZN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AstraZeneca Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在阿斯利康吗？</h2>
</div><p>Before you consider AstraZeneca, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿斯利康之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿斯利康并不在名单上。</p>
</div><p>While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿斯利康目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Assenagon Asset Management S.A. 出售了 569,162 股阿斯利康制药 $AZN